Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Gary Remington, Ofer Agid & George Foussias. (2011) Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Expert Review of Neurotherapeutics 11:4, pages 589-607.
Read now
Read now
Ofer Agid, George Foussias & Gary Remington. (2010) Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opinion on Pharmacotherapy 11:14, pages 2301-2317.
Read now
Read now
Robin Emsley. (2009) Drugs in development for the treatment of schizophrenia. Expert Opinion on Investigational Drugs 18:8, pages 1103-1118.
Read now
Read now
Articles from other publishers (35)
Nicholas D. Henkel, Xiajoun Wu, Sinead M. O’Donovan, Emily A. Devine, Jessica M. Jiron, Laura M. Rowland, Zoltan Sarnyai, Amy J. Ramsey, Zhexing Wen, Margaret K. Hahn & Robert E. McCullumsmith. (2022) Schizophrenia: a disorder of broken brain bioenergetics. Molecular Psychiatry 27:5, pages 2393-2404.
Crossref
Crossref
Masato Nakashima, Haruka Imada, Eri Shiraishi, Yuki Ito, Noriko Suzuki, Maki Miyamoto, Takahiko Taniguchi & Hiroki Iwashita. (2018)
Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in
N
-Methyl-d-Aspartate Receptor Antagonist–Induced Rat Models of Schizophrenia
. Journal of Pharmacology and Experimental Therapeutics 365:1, pages 179-188.
Crossref
Crossref
Carlos Forray & Raimund Buller. (2017) Challenges and opportunities for the development of new antipsychotic drugs. Biochemical Pharmacology 143, pages 10-24.
Crossref
Crossref
Fabiana Maria das Gra?as Corsi-Zuelli, Fernanda Brognara, Gustavo Fernando da Silva Quirino, Carlos Hiroji Hiroki, Rafael Sobrano Fais, Cristina Marta Del-Ben, Luis Ulloa, Helio Cesar Salgado, Alexandre Kanashiro & Camila Marcelino Loureiro. (2017) Neuroimmune Interactions in Schizophrenia: Focus on Vagus Nerve Stimulation and Activation of the Alpha-7 Nicotinic Acetylcholine Receptor. Frontiers in Immunology 8.
Crossref
Crossref
Juliana S. Cassoli, Paul C. Guest, Aline G. Santana & Daniel Martins-de-Souza. (2016) Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia. PROTEOMICS - Clinical Applications 10:4, pages 442-455.
Crossref
Crossref
Carmen Klein Herenbrink, David A. Sykes, Prashant Donthamsetti, Meritxell Canals, Thomas Coudrat, Jeremy Shonberg, Peter J. Scammells, Ben Capuano, Patrick M. Sexton, Steven J. Charlton, Jonathan A. Javitch, Arthur Christopoulos & J. Robert Lane. (2016) The role of kinetic context in apparent biased agonism at GPCRs. Nature Communications 7:1.
Crossref
Crossref
Naren P. Rao & Ganesan Venkatasubramanian. 2015. Obsessive-Compulsive Symptoms in Schizophrenia. Obsessive-Compulsive Symptoms in Schizophrenia
135
146
.
Todd S. Woodward, Kwanghee Jung, Geoffrey N. Smith, Heungsun Hwang, Alasdair M. Barr, Ric M. Procyshyn, Sean W. Flynn, Mark van der Gaag & William G. Honer. (2013) Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis. European Archives of Psychiatry and Clinical Neuroscience 264:8, pages 673-682.
Crossref
Crossref
Michael De Santis, Bo Pan, Jiamei Lian, Xu-Feng Huang & Chao Deng. (2014) Different effects of Bifeprunox, Aripiprazole, and Haloperidol on body weight gain, food and water intake, and locomotor activity in rats. Pharmacology Biochemistry and Behavior 124, pages 167-173.
Crossref
Crossref
Anton A. H. P. Megens, Herman M. R. Hendrickx, Michel M. A. Mahieu, Annemie L. Y. Wellens, Peter Boer & Greet Vanhoof. (2014)
PDE
10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways
. Pharmacology Research & Perspectives 2:4.
Crossref
Crossref
H.-J. Möller, F. Seemüller, R. Schennach-Wolff, S. Stübner, E. Rüther & R. Grohmann. (2013) History, background, concepts and current use of comedication and polypharmacy in psychiatry. The International Journal of Neuropsychopharmacology 17:07, pages 983-996.
Crossref
Crossref
Jodi E. Gresack, Patricia A. Seymour, Christopher J. Schmidt & Victoria B. Risbrough. (2013) Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating. Psychopharmacology 231:10, pages 2189-2197.
Crossref
Crossref
Pawel ZajdelAnna Partyka, Krzysztof Marciniec, Andrzej J Bojarski, Maciej Pawlowski & Anna Wesolowska. (2014) Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?. Future Medicinal Chemistry 6:1, pages 57-75.
Crossref
Crossref
S. Farooq, O. Agid, G. Foussias & G. Remington. (2013) Using Treatment Response to Subtype Schizophrenia: Proposal for a New Paradigm in Classification. Schizophrenia Bulletin 39:6, pages 1169-1172.
Crossref
Crossref
Brian V. Broberg, Kristoffer H. Madsen, Niels Plath, Christina K. Olsen, Birte Y. Glenthøj, Olaf B. Paulson, Börje Bjelke & Lise V. Søgaard. (2013) A schizophrenia rat model induced by early postnatal phencyclidine treatment and characterized by Magnetic Resonance Imaging. Behavioural Brain Research 250, pages 1-8.
Crossref
Crossref
Seiya Miyamoto. 2010. Encyclopedia of Psychopharmacology. Encyclopedia of Psychopharmacology
1
5
.
Ross J. BaldessariniRoss J. Baldessarini. 2013. Chemotherapy in Psychiatry. Chemotherapy in Psychiatry
31
88
.
S Miyamoto, N Miyake, L F Jarskog, W W Fleischhacker & J A Lieberman. (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry 17:12, pages 1206-1227.
Crossref
Crossref
Zeynep Yilmaz, Clement C. Zai, Rudi Hwang, Steve Mann, Tamara Arenovich, Gary Remington & Zafiris J. Daskalakis. (2012) Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: A meta-analysis. Schizophrenia Research 140:1-3, pages 214-220.
Crossref
Crossref
H. A. Tejeda, T. S. Shippenberg & R. Henriksson. (2011) The dynorphin/κ-opioid receptor system and its role in psychiatric disorders. Cellular and Molecular Life Sciences 69:6, pages 857-896.
Crossref
Crossref
Cara R. Rabin & Steven J. Siegel. 2012. Current Antipsychotics. Current Antipsychotics
267
298
.
Sridhar Natesan, Greg E. Reckless, Karen B. L. Barlow, José N. Nobrega & Shitij Kapur. (2010) Partial agonists in schizophrenia – why some work and others do not: insights from preclinical animal models. The International Journal of Neuropsychopharmacology 14:09, pages 1165-1178.
Crossref
Crossref
Katherine Seto, Jane Dumontet & Mary H H Ensom. (2011) Risperidone in Schizophrenia: Is There a Role for Therapeutic Drug Monitoring?. Therapeutic Drug Monitoring 33:3, pages 275-283.
Crossref
Crossref
Francisco López-Muñoz & Cecilio Álamo. (2011) Neurobiological Background for the Development of New Drugs in Schizophrenia. Clinical Neuropharmacology 34:3, pages 111-126.
Crossref
Crossref
Jean-Martin Beaulieu & Raul R. Gainetdinov. (2011) The Physiology, Signaling, and Pharmacology of Dopamine Receptors. Pharmacological Reviews 63:1, pages 182-217.
Crossref
Crossref
Lin Pei, Shupeng Li, Min Wang, Mustansir Diwan, Hymie Anisman, Paul J Fletcher, José N Nobrega & Fang Liu. (2010) Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nature Medicine 16:12, pages 1393-1395.
Crossref
Crossref
Charles S. Elmore, Peter N. Dorff & J. Richard Heys. (2010)
Syntheses of the tricyclic cores of clozapine, dibenzo[b,f][1,4]thiazepin‐11(10H)‐one, and dibenzo[b,f][1,4]oxazepin‐11(10H)‐one in C‐14 labeled form by [
14
C]carbonylation
. Journal of Labelled Compounds and Radiopharmaceuticals 53:13, pages 787-792.
Crossref
Crossref
Seyed-Hesameddin Abbasi, Haleh Behpournia, Aboulfazl Ghoreshi, Bahman Salehi, Maedeh Raznahan, Shams-Ali Rezazadeh, Farzin Rezaei & Shahin Akhondzadeh. (2010) The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial. Schizophrenia Research 116:2-3, pages 101-106.
Crossref
Crossref
Laura Musazzi, Marco Milanese, Pasqualina Farisello, Simona Zappettini, Daniela Tardito, Valentina S. Barbiero, Tiziana Bonifacino, Alessandra Mallei, Pietro Baldelli, Giorgio Racagni, Maurizio Raiteri, Fabio Benfenati, Giambattista Bonanno & Maurizio Popoli. (2010) Acute Stress Increases Depolarization-Evoked Glutamate Release in the Rat Prefrontal/Frontal Cortex: The Dampening Action of Antidepressants. PLoS ONE 5:1, pages e8566.
Crossref
Crossref
Gary Remington, George Foussias & Ofer Agid. (2010) Progress in Defining Optimal Treatment Outcome in Schizophrenia. CNS Drugs 24:1, pages 9-20.
Crossref
Crossref
Marie-Noëlle Vacheron-Trystram, Françoise Cornic & Raphaël Gourevitch. 2010. La prise en charge des états réputés dangereux. La prise en charge des états réputés dangereux
97
152
.
Michael S. Ritsner. 2010. Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Brain Protection in Schizophrenia, Mood and Cognitive Disorders
343
395
.
Jim van Os & Shitij Kapur. (2009) Schizophrenia. The Lancet 374:9690, pages 635-645.
Crossref
Crossref
Fa?za Benaliouad, Shitij Kapur, Sridhar Natesan & Pierre-Paul Rompr?. (2009) Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion. European Neuropsychopharmacology 19:6, pages 416-430.
Crossref
Crossref
Falko Biedermann & W Wolfgang Fleischhacker. (2009) Antipsychotics in the early stage of development. Current Opinion in Psychiatry 22:3, pages 326-330.
Crossref
Crossref